The present invention provides a method for treating an ocular disease or condition in a subject, comprising administering to the subject’s ocular tissue a composition comprising an effective amount of one or more bioactive agents, wherein the composition is administered with a single-chamber or multi-chamber microchannel delivery device.

The present invention provides a method for treating an ocular disease or condition in a subject, comprising administering to the subject’s ocular tissue a composition comprising an effective amount of one or more bioactive agents, wherein the composition is administered with a single-chamber or multi-chamber microchannel delivery device.

The present application relates to a method for inducing neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy such as Hirschsprung disease (HSCR) or intestinal hypoganglionosis through the administration of an effective dose of recombinant Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide into the distal colon of the subject. The method also permits to correct the imbalance of nitrergic and cholinergic neuron subtypes located upstream of the aganglionic or hypoganglionic segment and restore distal colon function (e.g., motility and epithelial barrier) in the subject.

Object of the present invention is a drug delivery system comprising a decellularized corneal stroma scaffold having dispersed within and/or bound to its surface microparticles containing at least one pharmaceutically active molecule dispersed in a matrix having a composition consisting for at least 70% of polylactic co-glycolic acid (PLGA).

Disclosed herein are nerve xenografts and methods of using such for repairing and/or protecting a nerve tissue in a human patient. The subject matter disclosed herein generally relates to nerve xenografts derived from genetically engineered source animals, and use of such nerve xenografts for repairing and/protecting nerve tissue in a human patient, e.g., for reconstruction of large peripheral nerve gaps, treatment of spinal cord injuries and ailments, and other therapies.

The present invention provides a non-natural polypeptide for use in treatment and/or prevention of an ophthalmic disorder in a mammalian subject. Administration of the polypeptide is well tolerated by the mammal. The non-natural polypeptide is provided at high purity.

Provided herein are compositions that include one or more adeno-associated virus (AAVs) vectors and methods of inducing differentiation of a hair cell using these vector(s).

The present disclosure generally relates to the field of infertility, and in particular male infertility. Accordingly, the present disclosure provides for compositions and methods for managing male infertility, caused by erectile dysfunction. More particularly, the present disclosure provides a therapeutic composition comprising a platelet rich plasma (PRP) or a growth factor concentrate derived therefrom and a thermoresponsive polymer. The present disclosure also relates to the compositions of PRP and the concentrate themselves. Consequently, methods to obtain the said compositions, along with therapeutic applications for treatment of erectile dysfunction are also provided.

Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well as manufacture of compositions, medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.

The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.